Arcum Vision™

Pioneering the Next Generation of Ophthalmic Antimicrobial Therapeutics

We’re excited to share a glimpse into the future of treating ocular infections with our portfolio of cutting-edge antimicrobial therapies.

Designed with unparalleled efficacy, our lead technology, AV2019F2 Ophthalmic Solution, represents a breakthrough in our ability to combat blinding corneal infections.

eye image

We’re excited to share a glimpse into the future of treating ocular infections with our portfolio of cutting-edge antimicrobial therapies.

Designed with unparalleled efficacy, our lead technology, AV2019F2 Ophthalmic Solution, represents a breakthrough in our ability to combat blinding corneal infections.

eye image

The Problem we are Solving

1M patients

1M patients in the US and 10M worldwide present with vision-threatening infection symptoms every year1.

90% resistant infections

Antibiotic resistance is on the rise. Over 90 % of MRSA (methicillin-resistant Staphylococcus aureus) and multi drug resistant “superbug” ocular infections are resistant to FDA-approved antibiotics2.

80% off label Use

80% of US ophthalmologists use antimicrobial therapies off label because existing approved treatments are ineffective or resistant3.

only 1 FDA Approval

Within the last 20 years, only ONE new antibiotic ophthalmic drug was approved by the FDA4.

Novel Therapies

Novel ophthalmic antimicrobial therapies are desperately needed to stay ahead of emerging “superbugs” and save vision.

Introducing a breakthrough in the treatment of ocular infections

After hundreds of thousands of antimicrobial combination trials, we discovered AV2019F2, a patented ophthalmic formulation combining Polymyxin B, Trimethoprim, and Rifampin.

Arcum Vision™

Driven to develop the next
generation of Antimicrobial Eye Care

Arcum Vision was formed in 2021 with the mission of arming physicians with the next generation of antimicrobial therapeutics to treat blinding infections.

References

1Collier SA et al. Estimated burden of keratitis–United States, 2010. MMWR. Morbidity and mortality weekly report 63, 1027-1030 (2014)
2Austin et al. BMJ Open Ophthalmol. 2017 Aug 16;2(1):e000047
3Laskey et al. Efficacy of a novel ophthalmic antimicrobial drug combination toward a large panel of Staphylococcus aureus clinical ocular isolates from around the world. Cornea, 2020. 39(10) 1278-1284
4Asbell et al. Antibiotic resistance among ocular pathogens in the United States: Five-year results from the antibiotic resistance monitoring in ocular microorganisms (ARMOR) surveillance study. JAMA Ophthalmology. 2015. 133(12): 1445-54